New Report Available on Government Intervention in the Pharmaceuticals Market
Posted on: Wednesday, 23 May 2007, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c57778) has announced the addition of a new Decision Resources report, Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007 to their offering.
In the first quarter of 2007, political intervention in drug pricing and reimbursement in the world's major pharmaceutical markets greatly increased. In the United States, for example, a new Democratic majority in Congress is intent on curbing the prices of branded medicines and facilitating the launch of generic drugs. In the United Kingdom, a complete overhaul of the country's pricing and reimbursement system has been proposed. The goal in all major pharmaceutical markets is to cut health care costs, and the pharmaceutical industry is an easy target.
Questions Answered in This Spectrum Report:
- In January 2007, U.S. lawmakers proposed a series of bills to improve U.S. consumers' access to low priced generic drugs, including bio generics. Which bills have been proposed, how much savings are they purported to offer, and what are their chances of being made into law?
- According to the Centers for Medicare and Medicaid Services, the Medicare Part D prescription drug benefit is saving beneficiaries an average of $1,200 per year. On January 12, 2007, in a further attempt to lower drug prices, the House of Representatives passed the Medicare Prescription Drug Price Negotiation Act of 2007, which would empower the Department of Health and Human Services to negotiate Medicare Part D drug prices. What is the Congressional Budget Office's argument against this proposal?
- In February 2007, the United Kingdom's Office of Fair Trading (OFT) published a highly critical review of the Pharmaceutical Price Regulation Scheme, which controls the level of profit companies may make on sales of branded prescription drugs to the National Health Service. What were the OFT's criticisms, and what two options did the agency propose to better control prescription drug prices?
- The announcement, in March 2007, by Japan's Ministry of Health, Labor, and Welfare that it is considering overhauling the national pricing and reimbursement system has galvanized the international pharmaceutical industry, which has long been critical of the system. What reforms is the Federation of Pharmaceutical Manufacturers' Associations of Japan planning to propose?
Scope:
- First quarter news in 2007: major events in the pharmaceutical pricing, reimbursement, and prescribing environment in the United States, Europe (France, Germany, Italy, Spain, and the United Kingdom), and Japan.
- Cost-containment programs: legislation that has been proposed in the United States and elsewhere to reduce drug expenditures and make medication more affordable to patients.
- Outlook: our assessment of the implications of these events for the pharmaceutical industry in the major markets under study.
Content Outline:
Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
United States
Slowdown in U.S. Health Care Spending in 2005
Solid Growth in U.S. Pharmaceutical Market in 2006
Increased Scrutiny of Drug Prices for Federal Programs
Continued Growth in Medicare Part D Enrollment
Pressure for Government Price Negotiations for Medicare Part D
Prospect of Increased Medicaid Rebates
Measures to Improve Access to Generic Drugs
Regulation of Biogenerics
Drug Importation
France
National Frame of Reference for the Good Use of Expensive and Innovative Drugs
Parallel Imports
Obesity Therapy Qualifies for Limited Reimbursement
GlaxoSmithKline Fined for Predatory Pricing
Germany
Slowdown in Pharmaceutical Spending
New Health Care Reforms Enacted
Growth of Manufacturer Rebates
Daily Cost-of-Therapy Limits
Italy
Concern over Regional Reference Pricing Initiatives
Industry Calls for a Change in Pharmaceutical Policy
Spain
Implementation of New Reference Pricing System
New System to Monitor Parallel Exports
United Kingdom
Proposal to Replace the Pharmaceutical Price Regulation Scheme
New Candidates for Single Technology Appraisals
Adjustments to Prescription Charges
Japan
Expected Reform of the Pricing and Reimbursement System
Limited Level of Generics Substitution
Outlook and Implications for the Pharmaceutical Industry
Figures
1. Evolution of Prescription Drug Expenditures in the United States in Select Years from
1970 to 2005
2. Main Sources of Funding for U.S. Prescription Drug Expenditures, 2005
3. Medicare Beneficiaries' Prescription Drug Coverage, January 2007
Companies Mentioned:
- Abbott
- Amgen
- Apotex
- AstraZeneca
- Bristol-Myers Squibb
- Express Scripts
- Genentech
- GlaxoSmithKline
- IMS Health
- Roche
- Sanofi -Aventis
- Schering-Plough
- Servier
- Takeda
- UCB
For more information visit http://www.researchandmarkets.com/reports/c57778
Source: Business Wire
Related Articles
- RetireSafe Salutes Pharmaceutical Research and Manufacturers of America for Its Commitment to Cut Drug Prices and Help Seniors in the Medicare 'Doughnut-Hole'
- Prescription Drug Price Regulations May Shorten Life Span
- 'Access to Hospital Pharmaceutical Markets in the United Kingdom' - the Hospital Drug Bill Has Been Rising at More Than Twice the Rate of GP Prescribing Costs
- CIGNA Pharmacy Management Receives Two Awards for Prescription Drug Price Quote Tool
- Prescription Drug Price Comparison Toolbar
- Senate Blocks Medicare Drug Price Bill
- Bush Would Veto Medicare Drug Price Bill
- Fitch Teleconf: 2007 Nonprofit and Health Care Systems Outlook, 1/11/07 2pm ET
- Report: Prescription Drug Prices Hiked
- Prescription Drug Prices Still Outpacing Inflation
 |
 |
User Comments (0)
RSS Feeds